285 The Risk Factors Associated with Liver Injury and the Impact of Liver Injury On Transplant Related Mortality in Pediatric Recipients of Allogeneic Hematopoietic Stem Cell Transplantation

Track: Contributed Abstracts
Wednesday, February 13, 2013, 6:45 PM-7:45 PM
Hall 1 (Salt Palace Convention Center)
Kavita Radhakrishnan , Yale Medical school, New Haven, CT
Jacquelyn Bishop, BS , Pediatrics, New York Presbyterian Hospital, NewYork
Zhezhen Jin, PhD , Columbia University, New York
Komal Kothari, BS , Columbia University, NY
Monica Bhatia, MD , Pediatric Blood and Marrow Transplantation, Columbia University, New York, NY
Diane George, MD , Pediatric Blood and Marrow Transplantation, Children's Hospital of New York, New York, NY
James Garvin, MD, PhD , Pediatrics, Columbia University/New York-Presbyterian Hospital, New York, NY
Mercedes Martinez, MD , Columbia University, NY
Nadia Ovchinsky, MD , Columbia University, NY
Steven Lobritto , Columbia University, NY
Yasmin Elsayed, MS , pediatrics, Columbia University, New York
Prakash Satwani, MD , Pediatrics, Columbia University, New York, NY
In adults, hepatic complications following allogeneic hematopoietic stem cell transplantation (AlloHSCT) are associated with significant morbidity and transplant related mortality (TRM). However, there is a paucity of parallel data on the incidence of, and risk factors for, liver injury (LI) and the impact of LI on TRM in pediatric AlloHSCT recipients. Methods: We compared total bilirubin, direct bilirubin and alanine aminotransferase values pre-AlloHSCT and at 1month, day +100  and 12 months post-AlloHSCT in 248 patients following myeloablative conditioning (MAC) or reduced toxicity/reduced intensity conditioning (RTC/RIC). Liver injury was defined as ≥ Grade 2 toxicities according to the NCI CTCAE 3.0/4.0 or total bilirubin 1.95mg/dL (1.5 times above upper limit of normal). Univariate and multivariate logistic regression models were used to identify risk factors for the incidences of LI and TRM. Results: 248 eligible patients received MAC (n=109) or RTC/RIC AlloHSCT (n=139). The incidence of LI at 1 month post-AlloSCT was significantly higher in MAC vs. RTC/RIC AlloHSCT based on total bilirubin levels (21.9% vs. 7.8%; p=0.0067). There was no significant difference in LI pre-AlloHSCT, LI  at day +100 and 12 months post-AlloHSCT between the two groups. The TRM among patients with LI at 1 month post-AlloHSCT was as 64.2% (CI95  49%, 79.4%) compared to 19% (CI95 11.8, 26.1%) (p<.0001) for those who did not have LI at 1 month post- AlloHSCT. On multivariate analysis, only bloodstream bacterial infections (p=0.0059) and invasive fungal infections (p=0.0020) were significant risk factors for developing LI at 1 month. On multivariate analysis for risk factors for TRM, only LI at 1 month post-AlloHSCT (p=0.0001), primary graft failure (p=0.0096) and bloodstream bacterial infections (p=.0328) were significant. However, LI prior to AlloHSCT conditioning was not associated with higher TRM. Conclusions: TRM among pediatric patients with LI at 1 month post-AlloHSCT is extremely high, with infections being the primary risk factor for LI.